Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011

Marina Biotech, Inc. to Present at the ROTH 23rd Annual OC Growth Stock Conference


//health-fitness.news-articles.net/content/2011/ .. roth-23rd-annual-oc-growth-stock-conference.html
Published in Health and Fitness on Tuesday, March 8th 2011 at 6:07 GMT by Market Wire   Print publication without navigation


BOTHELL, WA--(Marketwire - March 8, 2011) - Marina Biotech, Inc. (NASDAQ: [ MRNA ]), a leading RNAi-based drug discovery and development company, announced today that it will present at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, 2011, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time) at the Ritz-Carlton in Laguna Niguel, CA. J. Michael French, Marina Biotech President and Chief Executive Officer, will present a corporate overview and business update.

A live audio webcast will be available on the Event Calendar pages of the Investors section of the Company's website at [ http://www.marinabio.com ]. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the Marina Biotech website under Event Calendar approximately one hour after the live presentation.

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi- and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at [ http://www.marinabio.com ].


Publication Contributing Sources